Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
At the 6-month mark, the high-dose group saw a 3035% increase in mean glutathione levels within erythrocytes (red blood cells), plasma, and lymphocytes, and a massive 260% increase in buccal cells
Subcutaneous protocols are more common for musculoskeletal injuries but are also used for inflammatory bowel conditions
Obesity is associated with multiple comorbidities and is a major contributor to reduced life expectancy and quality of life
What's New: August 2026 Update TRIUMPH-2 confirmed (July 23, 2026): Obesity + type 2 diabetes trial, 1,152 patients up to 20.8% weight loss and up to 1.6 percentage points HbA1c reduction at 80 weeks TRIUMPH-3 confirmed (July 23, 2026): Obesity + established cardiovascular disease trial, 1,949 patients up to 22.6% weight loss at 80 weeks, plus significant improvements in triglycerides, blood pressure, and inflammatory markers All four core TRIUMPH trials are now complete TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4 have all reported positive topline results TRIUMPH-4 confirmed: 28.7% weight loss at 68 weeks in 445 participants topline results announced December 2025 TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients the pivotal general obesity trial met all primary and key secondary endpoints TRIUMPH-1 extension: In a prespecified 104-week extension, patients with BMI 35 reached 30.3% average weight loss no plateau observed TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First dedicated Phase 3 diabetes trial -2.0% HbA1c and 16.8% weight loss in 537 type 2 diabetes patients OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic now expected Q1 2027 (shifted from the previously estimated Q4 2026) Efficacy Summary Across All Completed Trials Phase 2: The Foundation (2023) The Phase 2 trial, published in the New England Journal of Medicine in June 2023, evaluated retatrutide in 338 adults with obesity (BMI 30) or overweight (BMI 27) with weight-related comorbidities
Managing Urinary Changes on Victoza If you notice changes in your urine whilst taking Victoza, several practical steps can help you manage the situation and determine whether further action is needed
Your B12 deficiency is as important as a folate or iron deficiency and should be treated as such
